Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2017 from OUS - Dept. of Microbiology, Cell signalling research group (Krauss)

4 publications found

Anumala UR, Waaler J, Nkizinkiko Y, Ignatev A, Lazarow K, Lindemann P, Olsen PA, Murthy S, Obaji E, Majouga AG, Leonov S, von Kries JP, Lehtiö L, Krauss S, Nazaré M (2017)
Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach
J Med Chem, 60 (24), 10013-10025
DOI 10.1021/acs.jmedchem.7b00883, PubMed 29155568

Lund K, Olsen CE, Wong JJW, Olsen PA, Solberg NT, Høgset A, Krauss S, Selbo PK (2017)
5-FU resistant EMT-like pancreatic cancer cells are hypersensitive to photochemical internalization of the novel endoglin-targeting immunotoxin CD105-saporin
J Exp Clin Cancer Res, 36 (1), 187
DOI 10.1186/s13046-017-0662-6, PubMed 29258566

Solberg NT, Waaler J, Lund K, Mygland L, Olsen PA, Krauss S (2017)
TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer
Mol Cancer Res, 16 (3), 543-553
DOI 10.1158/1541-7786.MCR-17-0362, PubMed 29222171

Vehus T, Waaler J, Krauss S, Lundanes E, Wilson SR (2017)
Combining HIC, SEC, and IEX with Fluorescence Polarization for Drug Target Discovery
LC GC Eur., 30 (5), 232-239

 
Page visits: 71227